Can the genetics of myeloma or other clinical factors predict who will progress from early conditions like MGUS and smoldering myeloma to active myeloma? Dr. Elisabet Manasanch of the MD Anderson Cancer Center is hosting a study in partnership with Signal Genetics/Quest to determine what is meaninfgul (or not) in determining who is most likely to progress and is thus most likely to receive treatment. Dr. Manasanch is also studying the new monoclonal antibody Isatuximab in a clinical trial for high-risk smoldering myeloma patients. The road to a cure may be earlier treatment in these precursor conditions while the disease is not as complex or aggressive. Learn more about this fascinating work to prevent myeloma from happening in the first place.